Factors associated with the severity of COVID-19 outcomes in people with neuromuscular diseases: Data from the International Neuromuscular COVID-19 Registry.
Factors associated with the severity of COVID-19 outcomes in people with neuromuscular diseases: Data from the International Neuromuscular COVID-19 Registry.
复制标题
DOI：
10.1111/ene.15613
复制
发表时间：
2023-02
影响因子：
5.1
通讯作者：
Machado, Pedro M.
中科院分区：
文献类型：
--
作者：
Pizzamiglio, Chiara;Pitceathly, Robert D. S.;Lunn, Michael P.;Brady, Stefen;De Marchi, Fabiola;Galan, Lucia;Heckmann, Jeannine M.;Horga, Alejandro;Molnar, Maria J.;Oliveira, Acary S. B.;Pinto, Wladimir B. V. R.;Primiano, Guido;Santos, Ernestina;Schoser, Benedikt;Servidei, Serenella;Souza, Paulo V. Sgobbi;Venugopalan, Vishnu;Hanna, Michael G.;Dimachkie, Mazen M.;Machado, Pedro M.
感染SARS - CoV - 2的神经肌肉疾病（NMDs）患者的临床结果信息有限。本研究的目的是确定nmd患者中与COVID - 19结局严重程度相关的因素。纳入了截至2021年12月31日提交给国际神经肌肉COVID - 19登记处的任何年龄的NMD病例和确诊/推定的COVID - 19病例。相互排斥的有序COVID - 19严重程度量表定义如下：(1)无住院治疗；(2)无氧住院；(3)通气/氧合住院；(4)死亡。使用多变量有序逻辑回归分析来估计严重结局的优势比（ORs），调整年龄、性别、种族/民族、NMD、合并症、基线功能状态（改良Rankin量表[mRS]）、使用免疫抑制/免疫调节药物和大流行日历期。来自13个国家的315例患者（平均年龄50.3[±17.7]岁，154例[48.9%]女性），175例（55.5%）未住院，27例（8.6%）住院时无补充氧气，91例（28.9%）住院时采用通气/补充氧气，22例（7%）死亡。年龄≥50岁（50 - 64岁：OR为2.4,95%可信区间[CI] 1.33-4.31；年龄≥64岁：OR为4.16,95%可信区间[CI] 2.12-8.15；两者均小于50岁）的患者出现严重COVID - 19结局的几率较高；非白人种族/民族（OR 1.81, 95% CI 1.07-3.06; vs.白人）；mRS中度重度/重度残疾（OR 3.02, 95% CI 1.6-5.69; vs.无/轻度/中度残疾）；呼吸功能障碍史（OR 3.16, 95% CI 1.79-5.58）；肥胖（OR 2.24, 95% CI 1.18-4.25）；≥3个合并症（OR 3.2, 95% CI 1.76-5.83；如果用合并症计数代替具体合并症）；糖皮质激素治疗（OR 2.33, 95% CI 1.14-4.78）；吉兰-巴罗综合征（OR 3.1, 95% CI 1.35-7.13；与线粒体疾病相比）。在nmd患者中，根据人口统计学和临床特征，COVID - 19结局的风险存在差异。这些发现可用于为NMD患者制定量身定制的管理策略和基于证据的建议。
Clinical outcome information on patients with neuromuscular diseases (NMDs) who have been infected with SARS‐CoV‐2 is limited. The aim of this study was to determine factors associated with the severity of COVID‐19 outcomes in people with NMDs. Cases of NMD, of any age, and confirmed/presumptive COVID‐19, submitted to the International Neuromuscular COVID‐19 Registry up to 31 December 2021, were included. A mutually exclusive ordinal COVID‐19 severity scale was defined as follows: (1) no hospitalization; (2) hospitalization without oxygenation; (3) hospitalization with ventilation/oxygenation; and (4) death. Multivariable ordinal logistic regression analyses were used to estimate odds ratios (ORs) for severe outcome, adjusting for age, sex, race/ethnicity, NMD, comorbidities, baseline functional status (modified Rankin scale [mRS]), use of immunosuppressive/immunomodulatory medication, and pandemic calendar period. Of 315 patients from 13 countries (mean age 50.3 [±17.7] years, 154 [48.9%] female), 175 (55.5%) were not hospitalized, 27 (8.6%) were hospitalized without supplemental oxygen, 91 (28.9%) were hospitalized with ventilation/supplemental oxygen, and 22 (7%) died. Higher odds of severe COVID‐19 outcomes were observed for: age ≥50 years (50–64 years: OR 2.4, 95% confidence interval [CI] 1.33–4.31; >64 years: OR 4.16, 95% CI 2.12–8.15; both vs. <50 years); non‐White race/ethnicity (OR 1.81, 95% CI 1.07–3.06; vs. White); mRS moderately severe/severe disability (OR 3.02, 95% CI 1.6–5.69; vs. no/slight/moderate disability); history of respiratory dysfunction (OR 3.16, 95% CI 1.79–5.58); obesity (OR 2.24, 95% CI 1.18–4.25); ≥3 comorbidities (OR 3.2, 95% CI 1.76–5.83; vs. ≤2; if comorbidity count used instead of specific comorbidities); glucocorticoid treatment (OR 2.33, 95% CI 1.14–4.78); and Guillain–Barré syndrome (OR 3.1, 95% CI 1.35–7.13; vs. mitochondrial disease). Among people with NMDs, there is a differential risk of COVID‐19 outcomes according to demographic and clinical characteristics. These findings could be used to develop tailored management strategies and evidence‐based recommendations for NMD patients.
登录
查看更多内容
DOI：
10.1056/nejmoa2022926
发表时间：
2020-11-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
RECOVERY Collaborative Group;Horby P;Mafham M;Linsell L;Bell JL;Staplin N;Emberson JR;Wiselka M;Ustianowski A;Elmahi E;Prudon B;Whitehouse T;Felton T;Williams J;Faccenda J;Underwood J;Baillie JK;Chappell LC;Faust SN;Jaki T;Jeffery K;Lim WS;Montgomery A;Rowan K;Tarning J;Watson JA;White NJ;Juszczak E;Haynes R;Landray MJ
通讯作者：
Landray MJ
DOI：
10.1016/j.clim.2020.108651
发表时间：
2021-03
期刊：
Clinical immunology (Orlando, Fla.)
影响因子：
--
作者：
Gasmi A;Peana M;Pivina L;Srinath S;Gasmi Benahmed A;Semenova Y;Menzel A;Dadar M;Bjørklund G
通讯作者：
Bjørklund G
影响因子：
3.9
作者：
Dresser L;Wlodarski R;Rezania K;Soliven B
通讯作者：
Soliven B
影响因子：
27.4
作者：
Alunno, Alessia;Najm, Aurelie;Mariette, Xavier
通讯作者：
Mariette, Xavier
DOI：
10.1002/art.41567
发表时间：
2021-03
期刊：
Arthritis & rheumatology (Hoboken, N.J.)
影响因子：
--
作者：
Gianfrancesco MA;Leykina LA;Izadi Z;Taylor T;Sparks JA;Harrison C;Trupin L;Rush S;Schmajuk G;Katz P;Jacobsohn L;Hsu TY;D'Silva KM;Serling-Boyd N;Wallwork R;Todd DJ;Bhana S;Costello W;Grainger R;Hausmann JS;Liew JW;Sirotich E;Sufka P;Wallace ZS;Machado PM;Robinson PC;Yazdany J;COVID-19 Global Rheumatology Alliance
通讯作者：
COVID-19 Global Rheumatology Alliance